CTCE-9908
- Availability: 24/48H Stock Items & 2 to 6 Weeks non Stock Items.
- Dry Ice Shipment: No


CTCE-9908
Description :
CTCE-9908 is a potent and selective CXCR4 antagonist. CTCE-9908 induces mitotic catastrophe, cytotoxicity and inhibits migration in CXCR4-expressing ovarian cancer cells[1][2].UNSPSC :
12352209Target :
CXCRType :
PeptidesRelated Pathways :
GPCR/G Protein; Immunology/InflammationApplications :
Cancer-programmed cell deathField of Research :
CancerAssay Protocol :
https://www.medchemexpress.com/ctce-9908.htmlPurity :
99.47Solubility :
H2O : 33.33 mg/mL (ultrasonic)Smiles :
OC(C=C1)=CC=C1C[C@H](NC([C@H](CO)NC([C@H](CC(C)C)NC([C@H](CO)NC([C@H](C(C)C)NC(CNC([C@@H](N)CCCCN)=O)=O)=O)=O)=O)=O)C(N[C@@H](CCCNC(N)=N)C(N[C@H](C(N)=O)CCCCNC([C@H](CCCNC(N)=N)NC([C@@H](NC([C@H](CO)NC([C@H](CC(C)C)NC([C@H](CO)NC([C@H](C(C)C)NC(CNC([C@@H](N)CCCCN)=O)=O)=O)=O)=O)=O)CC2=CC=C(C=C2)O)=O)=O)=O)=OMolecular Formula :
C86H147N27O23Molecular Weight :
1927.25References & Citations :
[1]Joseph Kwong, et al. An antagonist of the chemokine receptor CXCR4 induces mitotic catastrophe in ovarian cancer cells. Mol Cancer Ther. 2009 Jul;8 (7) :1893-905.|[2]Saima Hassan, et al. CXCR4 peptide antagonist inhibits primary breast tumor growth, metastasis and enhances the efficacy of anti-VEGF treatment or docetaxel in a transgenic mouse model. Int J Cancer. 2011 Jul 1;129 (1) :225-32.Shipping Conditions :
Blue IceStorage Conditions :
-80°C, 2 years; -20°C, 1 year (Powder, stored under nitrogen, away from moisture)Scientific Category :
PeptidesClinical Information :
Phase 2Isoform :
CXCR4CAS Number :
[1030384-98-5]

